Alto Neuroscience Investor Relations Material
Latest events
Investor Update
Alto Neuroscience
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Alto Neuroscience Inc
Access all reports
Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company based in the United States, focusing on developing precision medicine for psychiatric conditions. The company leverages AI-derived brain biomarkers to tailor psychiatric drug development to individual patients, aiming to improve treatment effectiveness for mental health issues. Their approach integrates detailed patient-specific data to optimize the drug development process. Alto Neuroscience has a range of products in clinical trials targeting conditions such as major depressive disorder and post-traumatic stress disorder. The company is headquartered in Los Altos, California, and its shares are listed on the NYSE under the ticker ANRO.
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
ANRO
Country
🇺🇸 United States